Latest Insider Transactions at Schrodinger, Inc. (SDGR)
This section provides a real-time view of insider transactions for Schrodinger, Inc. (SDGR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Schrodinger, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Schrodinger, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
1,393
+50.0%
|
$5,572
$4.34 P/Share
|
|
Sep 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
1,394
-100.0%
|
$85,034
$61.13 P/Share
|
|
Sep 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
1,394
+50.0%
|
$5,576
$4.34 P/Share
|
|
Sep 13
2021
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
15,602
-68.65%
|
$951,722
$61.62 P/Share
|
|
Sep 13
2021
|
Robert Lorne Abel Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,602
+50.0%
|
$265,234
$17.0 P/Share
|
|
Sep 02
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
3,874
-100.0%
|
$247,936
$64.62 P/Share
|
|
Sep 02
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,874
+50.0%
|
$15,496
$4.34 P/Share
|
|
Sep 01
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
1,700
-100.0%
|
$108,800
$64.53 P/Share
|
|
Sep 01
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+50.0%
|
$6,800
$4.34 P/Share
|
|
Aug 16
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
37,738
-78.74%
|
$2,151,066
$57.8 P/Share
|
|
Aug 16
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
37,738
+30.27%
|
$301,904
$8.19 P/Share
|
|
Aug 02
2021
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
12,000
-32.42%
|
$816,000
$68.27 P/Share
|
|
Jul 19
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
63,061
-0.26%
|
$4,225,087
$67.64 P/Share
|
|
Jul 16
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,000
-0.16%
|
$1,914,000
$66.94 P/Share
|
|
Jul 15
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
59,358
-0.32%
|
$3,917,628
$66.63 P/Share
|
|
Jul 14
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
5,574
-78.34%
|
$379,032
$68.44 P/Share
|
|
Jul 14
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,574
+50.0%
|
$22,296
$4.34 P/Share
|
|
Jul 14
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,051
-0.18%
|
$2,315,468
$68.45 P/Share
|
|
Jul 13
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,213
-0.16%
|
$3,636,123
$71.64 P/Share
|
|
Jul 12
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,930
-0.11%
|
$1,569,750
$75.22 P/Share
|
|
Jul 09
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,514
-0.07%
|
$638,550
$75.56 P/Share
|
|
Jul 08
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
48,410
-0.13%
|
$3,533,930
$73.4 P/Share
|
|
Jul 07
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,849
-0.13%
|
$2,397,977
$73.89 P/Share
|
|
Jul 06
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,230
-0.13%
|
$1,892,250
$75.5 P/Share
|
|
Jul 02
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,613
-0.1%
|
$1,414,588
$76.2 P/Share
|
|
Jul 01
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
41,575
-0.21%
|
$3,159,700
$76.52 P/Share
|
|
Jun 30
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
36,609
-0.28%
|
$2,782,284
$76.45 P/Share
|
|
Jun 29
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
28,708
-0.15%
|
$2,239,224
$78.53 P/Share
|
|
Jun 28
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
56,034
-0.28%
|
$4,426,686
$79.04 P/Share
|
|
Jun 25
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
220,394
-0.81%
|
$17,190,732
$78.31 P/Share
|
|
Jun 24
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
78,633
-0.57%
|
$6,133,374
$78.22 P/Share
|
|
Jun 23
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
53,946
-0.39%
|
$4,153,842
$77.06 P/Share
|
|
Jun 22
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
129,002
-0.45%
|
$9,804,152
$76.09 P/Share
|
|
Jun 21
2021
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
15,602
-100.0%
|
$1,154,548
$74.16 P/Share
|
|
Jun 21
2021
|
Robert Lorne Abel Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,602
+30.61%
|
$124,816
$8.09 P/Share
|
|
Jun 21
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
60,449
-0.17%
|
$4,473,226
$74.32 P/Share
|
|
Jun 18
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
52,784
-0.24%
|
$3,906,016
$74.75 P/Share
|
|
Jun 17
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,945
-0.18%
|
$3,895,875
$75.37 P/Share
|
|
Jun 16
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
37,195
-0.17%
|
$2,752,430
$74.29 P/Share
|
|
Jun 15
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
60,414
-0.2%
|
$4,470,636
$74.54 P/Share
|
|
Jun 14
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
43,463
-0.19%
|
$3,346,651
$77.52 P/Share
|
|
Jun 14
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
5,574
-77.27%
|
$429,198
$77.65 P/Share
|
|
Jun 14
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,574
+50.0%
|
$22,296
$4.34 P/Share
|
|
Jun 08
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
10,242
-96.09%
|
$768,150
$75.79 P/Share
|
|
Jun 08
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
10,242
+50.0%
|
$40,968
$4.34 P/Share
|
|
Jun 07
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
6,479
-100.0%
|
$485,925
$75.1 P/Share
|
|
Jun 07
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
6,479
+50.0%
|
$25,916
$4.34 P/Share
|
|
Jun 07
2021
|
Rosana Kapeller Libermann Director |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$75,000
$75.0 P/Share
|
|
Jun 07
2021
|
Rosana Kapeller Libermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$4,000
$4.34 P/Share
|
|
May 26
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
980
-0.01%
|
$67,620
$69.09 P/Share
|